Please login to the form below
Alector
This page shows the latest Alector news and features for those working in and with pharma, biotech and healthcare.
Biogen and Eisai pull plug on Alzheimer’s drug
One example is US biotech Alector, whose lead candidate AL002 targets a triggering receptor expressed on myeloid cells 2 (TREM2) and is based on a view that the disease is caused
Latest news
-
Alector kicks off next wave of biotech IPOs
Alector is pioneering immuno-neurology, a novel therapeutic that will treat a range of degenerative brain disorders by restoring healthy immune function to the brain. ... Hot on Alector’s heels is Stealth BioTherapeutics, which is aiming to raise $81
-
J&J and Bayer unveil new bioincubators
Places in J&J's bioincubators have already yielded funding and licensing deals for the likes of Alector, Bell Biosystems and Araxes Pharma.
-
J&J adds Manchester to partnering network
Alector is targeting key components of the pathological pathways that underlie Alzheimer's using monoclonal antibody technology via its strategic alliance with antibody discovery specialist Adimab. ... This agreement provides Alector with a lot of
More from news
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
Brain power: fresh approaches to Alzheimer’s drug discovery
Angus Grant, CEO of the Dementia Discovery Fund, said: “I am delighted that Alector, the first of DDF’s investments, has reached this significant milestone. ... Alector’s progress serves as a great illustration of how the DDF’s investment choices
More from intelligence
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Medical Editor
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Account Director
-
Competitive
- Nucleus Global announces a trio of promotions
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- Pfizer introduces new logo in a ‘shift from commerce to science’
- New study identifies drugs that are safe to use in COVID-19 treatment
- PHE study finds people who have had COVID-19 can still transmit the virus
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
Wisepress
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
